1

Haemonetics

#3057

Rank

$4.19B

Marketcap

US United States

Country

Haemonetics
Leadership team

Mr. Christopher A. Simon (CEO, Pres & Director)

Mr. Josep Lluis Llorens (Exec. VP of Global Manufacturing & Supply Chain)

Mr. Stewart W. Strong (Pres of Global Hospital)

Products/ Services
Biotechnology, Consulting, Health Care, Medical, Medical Device
Number of Employees
1,000 - 20,000
Headquarters
Boston, Massachusetts, United States
Established
1971
Company Registration
SEC CIK number: 0000313143
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
HAE
Social Media
Overview
Location
Summary
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
History

The company was founded in 1971. Haemonetics started out producing the containers and bags required for blood collection. The Latham Bowl was a disposable container that could automate the separation of blood by centrifugation. Through the 90's, the company added additional product lines and technologies. The company opened a manufacturing facility in Holbrook, Massachusetts in 1988.In 1995 the company purchased the Intravenous Solutions manufacturing facility in Union, South Carolina.Addition acquisitions grew the company and expanded its services. In the following years the company branched off to making the whole plasma collection station including the machine, supplies and software for plasma collection. These acquisitions included Edmonton-based Fifth Dimension Information Systems to gain entry into the blood and plasma software industry. Further acquisitions include Chicago-based Arryx in July 2006, Information Data Management, Inc. in January 2007, the acquisition of a division of Haemoscope in 2007, the acquisition of Infonale in July 2007, and, in 2009, Chico, California-based Altivation and Tucson, Arizona-based Sebra.On August 21, 2007, 5D and IDM were officially merged into a new subsidiary called Haemonetics Software Solutions. The employees at both Edmonton and Rosemont continue to work from their respective offices.

Further acquisitions included the April 2009 acquisition of Neoteric Technology Ltd and the April 2010 acquisition of California-based Global Med Technologies, Inc. Haemonetics acquired the Pall Corporation's transfusion medicine business on August 1, 2012 for ~$550 million.

Mission
Haemonetics is committed to advancing the science of patient care. Our goal is to help healthcare organizations provide the highest level of patient care while providing innovative solutions and best-in-class performance.
Vision
Haemonetics is committed to becoming the leading global provider of blood management solutions. We strive to develop innovative solutions that improve patient outcomes, reduce healthcare costs, and provide better healthcare experiences for all involved.
Key Team

Mr. James C. D'Arecca CPA (CFO, Exec. VP & Financial Officer)

Ms. Farris Maryanne Maunsell (VP, Chief Accounting Officer & Principal Accounting Officer)

Ms. Anila Lingamneni (Exec. VP & CTO)

Ms. Olga Guyette (Director of Investor Relations)

Carla Burigatto (VP of Communications)

Mr. Francis Tan (Sr. VP of Corp. Devel. & Planning)

Ms. Laurie A. Miller (Sr. VP & Chief HR Officer)

Recognition and Awards
Haemonetics has received numerous awards over the years, including the Frost & Sullivan Best Practices Award for U.S. Healthcare Equipment & Instrumentation and the Global Platt's Energy Excellence Award. Additionally, the company was named as one of the Best Companies To Work For by USA Today and was listed in the Deloitte Technology Fast 500 for three consecutive years.
References
Haemonetics
Leadership team

Mr. Christopher A. Simon (CEO, Pres & Director)

Mr. Josep Lluis Llorens (Exec. VP of Global Manufacturing & Supply Chain)

Mr. Stewart W. Strong (Pres of Global Hospital)

Products/ Services
Biotechnology, Consulting, Health Care, Medical, Medical Device
Number of Employees
1,000 - 20,000
Headquarters
Boston, Massachusetts, United States
Established
1971
Company Registration
SEC CIK number: 0000313143
Net Income
100M - 500M
Revenue
Above - 1B
Traded as
HAE
Social Media